Searched for
CIPLA NEWS
Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...
- Stocks in news: Groww, Tata Motors PV, Cipla, Varun Beverages and Axis BankThe Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Ant...
- Stocks in news: PB Fintech, LIC, Trent, Ola Electric, and CiplaIn a day of mixed economic signals, Indian markets displayed notable volatility before settling at a flat close. PB Fintech enjoyed a subst...
- Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the boardCipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamie...
- Buy Cipla, target price Rs 1735: Axis SecuritiesCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 129384.57 Crore) operating in Pharmaceuticals ...
- Buy Cipla, target price Rs 1830: Motilal OswalCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 124555.61 Crore) operating in Pharmaceuticals ...
- Buy Cipla, target price Rs 1660: ICICI SecuritiesCipla Ltd. key Products/Revenue Segments include Pharmaceuticals, Royalty Income, Other Operating Revenue, Export Incentives and Scrap for ...
- Cipla eyes acquisitions, inorganic partnerships in US marketCipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company a...
- Buy Cipla, target price Rs 1540: Motilal OswalCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 106223.84 Crore) operating in Pharmaceuticals ...
- Buy Cipla, target price Rs 1350: Prabhudas LilladherCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 102978.40 Crore) operating in Pharmaceuticals ...
- Torrent Pharma says it has no disclosure to make now on potential Cipla stake buy deal reportsTorrent Pharma has stated that it does not have any information to disclose under listing regulations, in response to reports about the com...
- Cipla promoters mull stake sale to top PE firms Blackstone, Baring Asia: ReportHowever, the company has issued a clarification, saying that "the company is not aware of any event that requires disclosure under Listing ...
- Cipla to invest 15 million euros in Germany’s Ethris to expand respiratory portfolioThe investment will facilitate a long-term strategic partnership between Cipla and Ethris for development of messenger RNA (mRNA)-based the...
- Cipla skids 4% on Jan-Mar earnings missThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- Q2 takeaways: Will Cipla’s earnings drive the stock further?Its India business grew by 17 per cent YoY with strong growth across the three businesses and continued servicing of patients with Covid-19...
- Stay away from mid-caps for the time being: Abhimanyu Sofat, IIFLThough there is a hope of reduction in taxation and direct tax reforms, the weekend statement is getting a lot of HNI community worried, sa...
- Cipla may see some demand coming back into its stock: Deepak Mohoni, trendwatchindia.comDeepak Mohoni, Director, trendwatchindia.com, in a chat with ET Now talks about Cipla.
Load More
